- $24.39bn
- $20.57bn
- $5.14bn
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Brief: Opzelura® (Ruxolitinib) Cream Becomes First Steroid-Free Topical Jak Inhibitor Approved In The European Union For Adults With Moderate Atopic Dermatitis
U.S. RESEARCH ROUNDUP-Boeing, Coca-Cola, PayPal
Incyte lifts annual revenue forecast after settlement with CMS
Incyte Corp reports results for the quarter ended June 30 - Earnings Summary
Incyte beats Q2 revenue estimates on strong product demand
Brief: UK's MHRA Approves Retifanlimab For Treatment Of Advanced Merkel Cell Skin Cancer
FDA clears Orca's blood cancer therapy to reduce stem cell transplant complications (updated)
US FDA approves Orca Bio's blood cancer therapy
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Incyte rises on positive EU panel opinion for eczema cream
U.S. STOCKS ON THE MOVE-Abbvie, AMC, Getty
U.S. STOCKS ON THE MOVE-Getty Images, Ecarx, Maplight Therapeutics
U.S. STOCKS ON THE MOVE-Definium, Regenxbio, Arcosa
U.S. STOCKS ON THE MOVE- Visteon, Incyte, Apogee
Brief: Incyte - Announces Agreement With CMS To Resolve Opzelura Medicaid Rebate Litigation - SEC Filing
Incyte rises as it settles Medicaid dispute with US government